drugset / Trial / NCT00308178
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Completed
66 enrolled
Harold J. Burstein, MD, PhD
Beth Israel Deaconess Medical Center · collabCelgene Corporation · collabMassachusetts General Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor.
Timeline
- Start
- 2006-03
- Primary completion
- 2006-09
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | — |